{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"polatuzumab vedotin"},{"type":"USBrandName","name":"Polivy"},{"type":"CodeName","name":"DCDS4501A"},{"type":"Synonym","name":"antibody-drug conjugate DCDS4501A"},{"type":"Synonym","name":"ADC DCDS4501A"},{"type":"CodeName","name":"FCU 2711"},{"type":"CodeName","name":"RG7596"},{"type":"CodeName","name":"Ro 5541077-000"},{"type":"CASRegistryName","name":"1313206-42-6"}],"definition":{"html":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin-piiq selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells.","text":"An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B-cell antigen receptor complex-associated protein beta chain (CD79B) conjugated, via a protease-cleavable peptide linker, to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity.  Upon administration, the monoclonal antibody moiety of polatuzumab vedotin-piiq selectively binds to CD79B, a protein which is abundantly expressed on the surface of B-cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. CD79B, a component of the B-cell receptor (BCR), plays a key role in B-cell receptor signaling and is expressed on the surface of almost all types of malignant B-cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/polatuzumabvedotin-piiq","text":"Polatuzumab Vedotin-piiq"},"nciConceptId":"C104153","nciConceptName":"Polatuzumab Vedotin","termId":695317,"name":"polatuzumab vedotin-piiq","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"polatuzumab-vedotin"}],"links":null}